Lapatinib in metastatic breast cancer. (Q37622978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

Lapatinib in metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

main subject

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author

Jean-Sébastien Frénel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

E Bourbouloux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D Berton-Rigaud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Sadot-Lebouvier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Zanetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Campone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

603-612

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

cites work

Cancer statistics, 2008

1 reference

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

21 January 2018

1 reference

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

21 January 2018

1 reference

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor

21 January 2018

1 reference

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

21 January 2018

1 reference

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

Effects of food on the relative bioavailability of lapatinib in cancer patients

21 January 2018

1 reference

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

21 January 2018

1 reference

Analysis of dermatologic events in patients with cancer treated with lapatinib.

21 January 2018

1 reference

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

21 January 2018

1 reference

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

21 January 2018

1 reference

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

21 January 2018

1 reference

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

21 January 2018

1 reference

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

21 January 2018

1 reference

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/WHE.09.54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19863462%20AND%20SRC:MED&resulttype=core&format=json